Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart,Marleen Keyaerts,Thomas Guiot,Patrick Flamen,Manuel Ruiz-Borrego,Agostina Stradella,Begoña Bermejo,Santiago Escriva-de-Romani, Lourdes Calvo Martínez,Nuria Ribelles, María Fernandez-Abad, Cinta Albacar,Marco Colleoni,Laia Garrigos, Manuel Atienza de Frutos,Florence Dalenc,Aleix Prat,Frederik Marmé,Peter Schmid,Khaldoun Kerrou,Sofia Braga, Petra Gener,Miguel Sampayo-Cordero,Javier Cortés,José Manuel Pérez-García,Antonio Llombart-CussacJournal of Nuclear Medicine(2024)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要